Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
Dr Reddy's Laboratories (NYSE: RDY ) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Dr Reddy's Laboratories reported a 5.6%
Rein Therapeutics submits regulatory filing with SEC. The filing may contain information on company operations or financials.
Rein Therapeutics submits regulatory filing with SEC. No details disclosed.